Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;22(1):2-11.
doi: 10.1016/j.clcc.2022.11.001. Epub 2022 Nov 4.

Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine

Ruveyda Ayasun  1 , Turcin Saridogan  2 , Ola Gaber  3 , Ibrahim Halil Sahin  4
Affiliations
Review

Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine

Ruveyda Ayasun et al. Clin Colorectal Cancer. 2023 Mar.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year overall survival of 11%. The disease is usually diagnosed at advanced stages, and systemic chemotherapy is the standard-of-care treatment for the majority of patients with PDAC. Although novel treatment options, such as targeted therapy and immunotherapy, have achieved substantial progress leading to practice-changing results, with FDA approvals for several solid tumors so far, the progress achieved for PDAC is relatively limited. Recent studies uncovered potential therapeutic targets for patients with PDAC, and potential therapeutic opportunities are currently being further examined. Herein, we review recent advances in systemic therapy regimens, including cytotoxic agents, targeted therapies, immunotherapy, and novel therapeutic options for managing patients with PDAC. We also elaborate on molecular profiling to guide treatment and existing therapeutic opportunities that may further advance the clinical care of patients with this devastating disease.

Keywords: Fusion genes; Immunotherapy; KRAS12C; Pancreatic adenocarcinoma; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

None of all authors.

Figures

Figure 1
Figure 1
Potentially actionable genetic alterations in pancreatic ductal adenocarcinoma
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72(1):7–33. - PubMed
    1. Quante AS, Ming C, Rottmann M, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5:2649–2656. - PMC - PubMed
    1. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet North Am Ed. 2016;388:73–85. - PubMed
    1. Sahin IH, Iacobuzio-Donahue CA, O’Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016;20:341–359. - PMC - PubMed
    1. Sahin IH, Askan G, Hu ZI, O’Reilly EM. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? Ann Oncol. 2017;28:2950–2961. - PMC - PubMed

MeSH terms